Evidence map›Paper›PMID 41777542›Full record

ArticleFrontiers in microbiology2026

First identification of an ST11-KL64 hypervirulent

Jiaoli Chen, Cheng Wang, Lingbin Wu, Ziling Lan, Mei Li, Jianfen Xu, Xiaolei Hu, Jiansheng Huang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jiaoli Chen *Department of Clinical Laboratory, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui, Zhejiang, China.
Cheng Wang *Department of Clinical Laboratory, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui, Zhejiang, China.
Lingbin WuDepartment of Clinical Laboratory, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui, Zhejiang, China.
Ziling LanDepartment of Clinical Laboratory, Lishui Second People's Hospital Affiliated to Wenzhou Medical University, Lishui, Zhejiang, China.
Mei LiDepartment of the School of Medical Technology and Information Engineering, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Jianfen XuDepartment of Clinical Laboratory, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui, Zhejiang, China.
Xiaolei HuDepartment of Clinical Laboratory, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui, Zhejiang, China.
Jiansheng HuangDepartment of Clinical Laboratory, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui, Zhejiang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The convergence of hypervirulence and carbapenem resistance in Methods: We characterized 27 NDM-producing Results: The surveillance detected high clonal diversity across 19 sequence types among the isolates. CRKP26 exhibited extensive drug resistance, with resistance to ceftazidime, cefepime, aztreonam, piperacillin-tazobactam, and amikacin and high-level carbapenem resistance, with MICs of 64 μg/mL for imipenem and 256 μg/mL for meropenem. This strain was susceptible only to polymyxin B and tigecycline. Whole-genome sequencing (WGS) of CRKP26 revealed that Conclusion: To our knowledge, this is the first report of a hypervirulent ST11-KL64

Indexed as

hypervirulent Klebsiella pneumoniaeKPC-2NDM-1OmpK36 GD mutationST11-KL64

Identifiers

PMID41777542
PMCPMC12950690

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.